Carlsmed (CARL) Stock Analysis & Winston Score
Carlsmed is a medical technology company that makes personalized surgical implants for spine surgery. It uses software and data to design custom hardware — like rods and spacers — that fit each patient's unique spine, rather than using standard off-the-shelf parts. Surgeons at hospitals across the United States are the main customers. The company earns money by selling these custom implants directly to hospitals and surgical centers on a per-procedure basis. It operates primarily in the U.S. spine surgery market, which is large but competitive, with established players like Medtronic and Zimmer Biomet. Carlsmed's edge is its software-driven personalization platform, which makes switching to a competitor harder once a surgeon adopts the workflow. However, the company is currently losing money — its operating margin is deeply negative — so the key risk is whether it can grow revenue fast enough to reach profitability before needing to raise additional capital.
Winston Score: 33/100 — Below Average
Below-average fundamentals — multiple weak pillars.
- Quality: Mixed (10/30)
- Growth: Mixed (6/20)
- Cash Flow: Weak (0/10)
- Stability: Good (5/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
